Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Novo Nordisk A/S, UnitedHealth Group, and Johnson & Johnson. Learn more about health care stocks.

Eli Lilly and Company logo

#1 - Eli Lilly and Company

NYSE:LLY - See Stock Forecast
Stock Price:
$916.33 (+$3.01)
Market Cap:
$870.88 billion
P/E Ratio:
112.8
Dividend Yield:
0.56%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 16 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$979.29 (6.9% Upside)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Eli Lilly and Company Stock

Pros

  • Eli Lilly and Co reported strong quarterly earnings, surpassing analysts' estimates by a significant margin, indicating robust financial performance.
  • The company has a high return on equity of 67.52%, showcasing efficient utilization of shareholder equity to generate profits.
  • Revenue for the quarter exceeded analysts' expectations, demonstrating strong demand for Eli Lilly and Co's pharmaceutical products.

Cons

  • Market volatility and economic uncertainties could impact the stock price of Eli Lilly and Co, leading to potential short-term fluctuations.
Novo Nordisk A/S logo

#2 - Novo Nordisk A/S

NYSE:NVO - See Stock Forecast
Stock Price:
$118.01 (+$0.20)
Market Cap:
$529.57 billion
P/E Ratio:
40.4
Dividend Yield:
0.60%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$145.17 (23.0% Upside)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Novo Nordisk A/S Stock

Pros

  • Novo Nordisk's stock price has shown resilience, currently trading at a stable level, indicating potential stability in the market.
  • Novo Nordisk has a strong track record of innovation in the pharmaceutical industry, consistently developing new products and treatments.
  • The company has a robust financial position with a high return on equity, indicating efficient use of shareholder funds.

Cons

  • Market volatility and regulatory uncertainties in the pharmaceutical sector could impact Novo Nordisk's stock performance.
  • Intense competition in the industry may put pressure on Novo Nordisk's market share and pricing power.
  • Fluctuations in currency exchange rates could affect Novo Nordisk's international operations and financial results.
UnitedHealth Group logo

#3 - UnitedHealth Group

NYSE:UNH - See Stock Forecast
Stock Price:
$571.30 (+$15.01)
Market Cap:
$527.55 billion
P/E Ratio:
37.9
Dividend Yield:
1.39%
Consensus Rating:
Buy (2 Strong Buy Ratings, 18 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$615.16 (7.7% Upside)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of UnitedHealth Group Stock

Pros

  • UnitedHealth Group has shown consistent growth in its stock price, reaching a one-year high of $607.94.
  • The company operates through multiple segments, including UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx, providing diversified revenue streams.
  • Recent hedge fund activities indicate increased interest and investment in UnitedHealth Group, showcasing confidence from institutional investors.

Cons

  • UnitedHealth Group's stock has a relatively high price-to-earnings ratio of 35.10, which may indicate an overvalued stock compared to industry peers.
  • The company's debt-to-equity ratio of 0.67 suggests a moderate level of financial leverage, which could pose risks during economic downturns.
  • While insider ownership is at 0.33%, indicating some alignment of interests, it may also signal limited insider confidence in significant stock price growth.
Johnson & Johnson logo

#4 - Johnson & Johnson

NYSE:JNJ - See Stock Forecast
Stock Price:
$164.28 (+$0.18)
Market Cap:
$395.37 billion
P/E Ratio:
10.3
Dividend Yield:
3.07%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 7 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$175.93 (7.1% Upside)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Johnson & Johnson Stock

Pros

  • Johnson & Johnson has a strong market capitalization of $385.77 billion, indicating stability and size in the market.
  • Recent increase in institutional ownership to 69.55% of the company's stock, showing confidence from large investors.
  • Consistent dividend payments over the years, providing investors with a reliable income stream.

Cons

  • Recent target price decrease by TD Securities from $195.00 to $185.00, indicating potential concerns in the market.
  • Multiple analyst downgrades from "strong-buy" to "hold," suggesting a shift in sentiment towards the company.
  • Competition in the healthcare field leading to pricing pressures and regulatory challenges for Johnson & Johnson.
AbbVie logo

#5 - AbbVie

NYSE:ABBV - See Stock Forecast
Stock Price:
$190.46 (-$1.40)
Market Cap:
$336.33 billion
P/E Ratio:
63.5
Dividend Yield:
3.19%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 13 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$198.00 (4.0% Upside)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of AbbVie Stock

Pros

  • AbbVie's stock price has been steadily increasing, reaching $193.57 on October 13, 2024, indicating positive market sentiment.
  • AbbVie's strong portfolio of pharmaceutical products, including Humira, Skyrizi, Rinvoq, and Imbruvica, provides diversified revenue streams.
  • Recent analyst ratings have been overwhelmingly positive, with multiple firms raising price targets and issuing buy ratings on AbbVie.

Cons

  • AbbVie's high debt-to-equity ratio of 8.51 may pose a risk in case of economic downturns or financial instability.
  • The company's PE ratio of 57.35 and PEG ratio of 2.65 suggest that the stock may be overvalued compared to industry peers.
  • AbbVie's beta of 0.63 indicates lower volatility compared to the market, potentially limiting short-term trading opportunities.
Merck & Co., Inc. logo

#6 - Merck & Co., Inc.

NYSE:MRK - See Stock Forecast
Stock Price:
$110.43 (-$1.10)
Market Cap:
$282.48 billion
P/E Ratio:
20.5
Dividend Yield:
2.81%
Consensus Rating:
Moderate Buy (3 Strong Buy Ratings, 9 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$133.00 (20.4% Upside)
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Merck & Co., Inc. Stock

Pros

  • Merck's recent strategic acquisitions have diversified its product portfolio, reducing dependency on any single product and potentially increasing revenue streams.
  • Merck's strong pipeline of innovative drugs, including potential breakthrough treatments in oncology and immunology, could drive future growth and profitability.
  • Merck's consistent dividend payments and history of dividend growth make it an attractive option for income-oriented investors seeking stability and income generation.

Cons

  • Merck faces intense competition in the pharmaceutical industry, which could impact its market share and pricing power, leading to potential revenue pressures.
  • Regulatory challenges and uncertainties, including drug approval delays or failures, could disrupt Merck's product development timelines and financial performance.
  • Merck's heavy reliance on a few key blockbuster drugs for a significant portion of its revenue exposes the company to risks associated with patent expirations and generic competition.
This man predicted today’s most valuable companies more than a decade ago. (Ad)

How could it be that one analyst called the rise of Apple, Microsoft, Nvidia, and many of today’s best performing stocks more than a decade ago? Some might say it was luck… Others will say he was in the right place at the right time. But looking back, this analyst has made some incredible calls over his career… In fact, right now, he’s the #1 ranked stock picker in North America… To earn that title he’s beat out more than 16,000 stock market professionals. So how does one man accomplish all that? If you were to ask him, he’d give the credit to his stock rating system…. A system that has a history of predicting which stocks could soon rise by 100% or more…

Check it out, just follow this link and enter your email address.
AstraZeneca logo

#7 - AstraZeneca

NASDAQ:AZN - See Stock Forecast
Stock Price:
$78.31 (+$0.46)
Market Cap:
$242.81 billion
P/E Ratio:
37.8
Dividend Yield:
1.25%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 7 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$89.75 (14.6% Upside)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of AstraZeneca Stock

Pros

  • AstraZeneca has a strong buy rating from multiple analysts, indicating positive sentiment towards the company's future performance.
  • The company's recent stock price of $77.35 presents a potential buying opportunity for investors looking to enter at a relatively lower price point.
  • AstraZeneca's focus on the discovery, development, and commercialization of prescription medicines positions it well in the biopharmaceutical industry, which has shown resilience and growth potential.

Cons

  • Despite some positive ratings, there are also sell ratings on AstraZeneca, indicating a level of uncertainty or risk associated with the company's performance.
  • The company's stock price has experienced fluctuations, with a 12-month low of $60.47 and a high of $87.68, suggesting potential volatility in the stock.
  • AstraZeneca's PEG ratio of 1.43 may indicate that the stock is currently overvalued based on its growth prospects, potentially limiting upside potential for investors.
Novartis logo

#8 - Novartis

NYSE:NVS - See Stock Forecast
Stock Price:
$116.56 (+$0.34)
Market Cap:
$237.55 billion
P/E Ratio:
14.8
Dividend Yield:
2.09%
Consensus Rating:
Reduce (0 Strong Buy Ratings, 0 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$120.70 (3.6% Upside)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Novartis Stock

Pros

  • Novartis AG has a strong track record of consistent quarterly earnings, beating analysts' estimates, which indicates financial stability and growth potential.
  • With a current stock price of $116.22, Novartis AG is trading near its 52-week high, showing positive momentum and potential for further price appreciation.
  • The company has a healthy return on equity of 34.56%, indicating efficient use of shareholder funds to generate profits.

Cons

  • Novartis AG's stock price has experienced fluctuations, with a beta of 0.57, indicating higher volatility compared to the market average.
  • The company's debt-to-equity ratio of 0.47 may raise concerns about its financial leverage and ability to manage debt obligations.
  • Novartis AG's price-to-earnings ratio of 15.68 may suggest that the stock is currently trading at a premium valuation, potentially limiting immediate upside for investors.
Thermo Fisher Scientific logo

#9 - Thermo Fisher Scientific

NYSE:TMO - See Stock Forecast
Stock Price:
$591.50 (-$9.02)
Market Cap:
$230.65 billion
P/E Ratio:
36.7
Dividend Yield:
0.26%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 17 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$656.16 (10.9% Upside)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Thermo Fisher Scientific Stock

Pros

  • Thermo Fisher Scientific Inc. has a strong track record of consistent earnings growth, with an expected EPS of 21.72 for the current fiscal year. This indicates financial stability and potential for future returns.
  • The company has a high percentage of institutional ownership at 89.23%, which signifies confidence from large investors and stability in the stock.
  • Recent insider selling activities totaling $14,094,292 may indicate that insiders believe the stock is overvalued, potentially prompting a correction in the stock price.

Cons

  • Insiders have sold a significant number of shares worth $14,094,292 over the last three months, which could be interpreted as a lack of confidence in the company's future performance.
  • The current stock price of Thermo Fisher Scientific Inc. may be inflated due to the high institutional ownership and positive analyst ratings, potentially leading to a price correction.
  • Thermo Fisher Scientific Inc.'s dividend yield of 0.26% may not be attractive to income-seeking investors compared to other dividend-paying stocks.
Abbott Laboratories logo

#10 - Abbott Laboratories

NYSE:ABT - See Stock Forecast
Stock Price:
$117.82 (+$1.77)
Market Cap:
$204.96 billion
P/E Ratio:
37.2
Dividend Yield:
1.89%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 10 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$125.54 (6.6% Upside)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Abbott Laboratories Stock

Pros

  • Abbott Laboratories has shown consistent revenue growth over recent quarters, indicating a strong financial performance.
  • The company has a diversified product portfolio across healthcare segments, reducing risk associated with dependence on a single product.
  • Abbott Laboratories has a solid track record of dividend payments, providing investors with a reliable income stream.

Cons

  • Abbott Laboratories operates in a highly regulated industry, subject to potential changes in healthcare policies that could impact profitability.
  • The company faces competition from other healthcare giants, which may limit market share growth and pricing power.
  • Fluctuations in currency exchange rates could affect Abbott Laboratories' international operations and financial results.
Amgen logo

#11 - Amgen

NASDAQ:AMGN - See Stock Forecast
Stock Price:
$321.63 (-$3.46)
Market Cap:
$172.53 billion
P/E Ratio:
55.4
Dividend Yield:
2.77%
Consensus Rating:
Hold (1 Strong Buy Ratings, 10 Buy Ratings, 12 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$326.95 (1.7% Upside)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Amgen Stock

Pros

  • Amgen Inc. has consistently shown strong financial performance, with a return on equity of 161.72% and a net margin of 10.12% in recent quarters. These metrics indicate the company's profitability and efficiency in generating earnings.
  • Amgen Inc. announced a quarterly dividend, with a yield of 2.83%. This dividend payout can provide investors with a steady income stream, enhancing the overall return on investment.
  • Analysts have issued positive ratings on Amgen Inc., with a consensus rating of "Moderate Buy" and an average price target of $326.30. This indicates confidence in the company's future growth potential.

Cons

  • Amgen Inc. has a relatively high debt-to-equity ratio of 9.64, which may indicate higher financial risk and potential constraints on future growth initiatives.
  • Despite positive analyst ratings, there is a sell rating on Amgen Inc.'s stock, suggesting some concerns or uncertainties in the market regarding the company's performance or outlook.
  • Amgen Inc.'s stock price has experienced fluctuations, with recent trading down by 0.2%. This volatility may pose challenges for investors seeking stable returns.
Intuitive Surgical logo

#12 - Intuitive Surgical

NASDAQ:ISRG - See Stock Forecast
Stock Price:
$476.59 (-$1.88)
Market Cap:
$169.05 billion
P/E Ratio:
81.9
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 14 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$474.16 (-0.5% Downside)
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Intuitive Surgical Stock

Pros

  • Intuitive Surgical, Inc. has a strong market position in the field of minimally invasive care, providing a competitive edge in the healthcare industry.
  • The company's stock price has shown consistent growth, reaching $480.79 on the trading day of October 14, 2024, indicating positive investor sentiment.
  • Analysts have given Intuitive Surgical, Inc. a "Moderate Buy" rating with an average price target of $454.35, suggesting further potential for stock appreciation.

Cons

  • Despite positive analyst ratings, there is always inherent risk in investing in the stock market, and past performance is not indicative of future results.
  • The company's stock has a high price-to-earnings ratio of 86.93, which may indicate an overvaluation compared to industry peers.
  • Intuitive Surgical, Inc. operates in a highly competitive market, facing potential challenges from new entrants or technological disruptions.
Pfizer logo

#13 - Pfizer

NYSE:PFE - See Stock Forecast
Stock Price:
$29.66 (+$0.22)
Market Cap:
$168.07 billion
Dividend Yield:
5.76%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 5 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$34.10 (15.0% Upside)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Pfizer Stock

Pros

  • Pfizer's recent quarterly earnings report exceeded expectations, with an EPS of $0.60, beating the consensus estimate by $0.14. This indicates strong financial performance.
  • Analysts have given Pfizer an average rating of "Moderate Buy" with a price target of $34.54, suggesting potential for stock price growth.
  • Pfizer announced a quarterly dividend of $0.42 per share, representing a yield of 5.73%. This can provide investors with a steady income stream.

Cons

  • Pfizer's dividend payout ratio is currently -2,800.00%, indicating that the company may not be effectively managing its dividend payments.
  • The company's P/E ratio is -496.00, which may suggest overvaluation or potential risks in the stock price.
  • While Pfizer's revenue was up 2.1% compared to the previous year, the growth rate may not be substantial enough to attract certain investors seeking higher returns.
Sanofi logo

#14 - Sanofi

NASDAQ:SNY - See Stock Forecast
Stock Price:
$54.44 (-$0.13)
Market Cap:
$137.88 billion
P/E Ratio:
29.6
Dividend Yield:
2.69%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$57.50 (5.6% Upside)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Sanofi Stock

Pros

  • Sanofi's recent EPS of $0.93 for the quarter exceeded analysts' consensus estimates by $0.05, indicating strong financial performance.
  • Sanofi's revenue growth of 7.8% year-over-year demonstrates positive momentum in the company's core business operations.
  • Analysts have raised their price targets for Sanofi, with a consensus rating of "Moderate Buy" and a price target of $57.50, suggesting potential upside.

Cons

  • Sanofi's revenue for the quarter fell short of analysts' consensus estimates, signaling potential challenges in meeting market expectations.
  • Sanofi's PE ratio of 28.96 and price-to-earnings-growth ratio of 1.62 may indicate the stock is currently trading at a premium valuation.
  • Sanofi's 1-year high of $58.97 suggests limited room for immediate capital appreciation based on historical price levels.
Stryker logo

#15 - Stryker

NYSE:SYK - See Stock Forecast
Stock Price:
$361.38 (+$2.40)
Market Cap:
$137.67 billion
P/E Ratio:
40.3
Dividend Yield:
0.89%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 15 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$381.16 (5.5% Upside)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Stryker Stock

Pros

  • Stryker Co. has shown consistent growth in revenue and profitability over the past few quarters, indicating a strong financial performance.
  • The company's innovative product pipeline, including the latest advancements in MedSurg and Neurotechnology, positions it well for future market expansion and revenue growth.
  • Recent insider transactions, such as the sale of shares at a higher price than the current market value, suggest confidence in the company's future prospects.

Cons

  • Market volatility and economic uncertainties could impact Stryker Co.'s stock price, leading to short-term fluctuations and potential investor concerns.
  • Increased competition in the medical technology sector may put pressure on Stryker Co.'s market share and margins, affecting its long-term growth prospects.
  • Regulatory changes or challenges in obtaining approvals for new products could delay product launches and impact revenue generation for Stryker Co.
Boston Scientific logo

#16 - Boston Scientific

NYSE:BSX - See Stock Forecast
Stock Price:
$87.02 (+$0.25)
Market Cap:
$127.66 billion
P/E Ratio:
70.7
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 17 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$88.55 (1.8% Upside)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Boston Scientific Stock

Pros

  • Boston Scientific Co. has shown consistent revenue growth, with a 14.5% increase in revenue year-over-year.
  • Analysts forecast a positive earnings per share of 2.4 for the current fiscal year, indicating profitability.
  • Recent institutional trading activity has seen large investors increasing their stakes in the company, signaling confidence in its future performance.

Cons

  • Despite positive analyst ratings, there is always a level of risk associated with investing in the stock market, including potential market volatility.
  • The company operates in the healthcare sector, which can be subject to regulatory changes and unpredictable market conditions.
  • Insider selling activity has been observed, with company executives selling shares, which could be perceived as a lack of confidence in the company's future prospects.
Vertex Pharmaceuticals logo

#17 - Vertex Pharmaceuticals

NASDAQ:VRTX - See Stock Forecast
Stock Price:
$487.25 (+$2.95)
Market Cap:
$125.76 billion
Consensus Rating:
Hold (0 Strong Buy Ratings, 17 Buy Ratings, 9 Hold Ratings, 3 Sell Ratings)
Consensus Price Target:
$488.92 (0.3% Upside)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Vertex Pharmaceuticals Stock

Pros

  • Vertex Pharmaceuticals stock has shown resilience, trading at $462.99 on October 10, 2024, with a market cap of $119.48 billion, indicating stability and potential growth.
  • Vertex Pharmaceuticals has a strong portfolio of therapies for treating cystic fibrosis, a chronic genetic disorder, which provides a steady revenue stream and growth potential.
  • Institutional investors and hedge funds own a significant portion (90.96%) of Vertex Pharmaceuticals stock, indicating confidence in the company's future performance.

Cons

  • Despite positive analyst ratings, some firms have issued sell ratings on Vertex Pharmaceuticals stock, indicating differing opinions on the company's future performance.
  • Insiders have been actively selling company stock in recent months, which could raise concerns about their confidence in the company's growth potential or future prospects.
  • While Vertex Pharmaceuticals has a strong focus on cystic fibrosis treatments, any setbacks in research and development or regulatory approvals could impact the company's revenue and stock performance.
Medtronic logo

#18 - Medtronic

NYSE:MDT - See Stock Forecast
Stock Price:
$89.99 (+$0.15)
Market Cap:
$115.39 billion
P/E Ratio:
30.4
Dividend Yield:
3.13%
Consensus Rating:
Hold (1 Strong Buy Ratings, 6 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$95.36 (6.0% Upside)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Medtronic Stock

Pros

  • Medtronic plc has consistently shown strong financial performance, with a solid return on equity of 13.68% and a healthy net margin of 12.06%, indicating efficient operations and profitability.
  • Recent analyst ratings have been positive, with multiple firms upgrading their outlook on Medtronic plc, including a "strong-buy" rating, which could indicate growing confidence in the company's future prospects.
  • Medtronic plc has a stable dividend payout, offering investors a dividend yield of 3.13%, providing a source of income in addition to potential capital appreciation.

Cons

  • Despite positive analyst ratings, there is a notable number of hold ratings on Medtronic plc, indicating uncertainty or caution among some analysts about the company's future performance.
  • The company's current P/E ratio of 32.48 and P/E/G ratio of 2.56 suggest that the stock may be trading at a premium compared to industry peers, potentially limiting immediate upside potential for investors.
  • Medtronic plc's debt-to-equity ratio of 0.55 may raise concerns about the company's leverage and financial risk, which could impact future growth and shareholder returns.
Elevance Health logo

#19 - Elevance Health

NYSE:ELV - See Stock Forecast
Stock Price:
$496.99 (+$13.12)
Market Cap:
$112.46 billion
P/E Ratio:
17.4
Dividend Yield:
1.28%
Consensus Rating:
Buy (1 Strong Buy Ratings, 13 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$605.07 (21.7% Upside)
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.
Regeneron Pharmaceuticals logo

#20 - Regeneron Pharmaceuticals

NASDAQ:REGN - See Stock Forecast
Stock Price:
$1,007.96 (-$8.57)
Market Cap:
$111.06 billion
P/E Ratio:
26.7
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 16 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$1,116.00 (10.7% Upside)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Regeneron Pharmaceuticals Stock

Pros

  • Regeneron Pharmaceuticals has a strong average rating of "Moderate Buy" with a consensus target price of $1,118.62, indicating positive sentiment from analysts.
  • Recent insider activity shows that the chief financial officer sold shares at a higher price, potentially signaling confidence in the company's future performance.
  • Institutional inflows have been observed, with various funds increasing their positions in Regeneron Pharmaceuticals, indicating institutional investor confidence in the company.

Cons

  • Multiple analysts have issued hold ratings on Regeneron Pharmaceuticals, potentially indicating uncertainty or limited short-term growth prospects.
  • Recent insider selling activity has been notable, with insiders selling a significant number of shares, which could raise concerns about insider sentiment.
  • While institutional inflows have been observed, the percentage of stock owned by institutional investors is relatively high at 83.31%, potentially limiting individual investor influence.
Bristol-Myers Squibb logo

#21 - Bristol-Myers Squibb

NYSE:BMY - See Stock Forecast
Stock Price:
$53.37 (+$0.61)
Market Cap:
$108.19 billion
Dividend Yield:
4.60%
Consensus Rating:
Reduce (0 Strong Buy Ratings, 1 Buy Ratings, 13 Hold Ratings, 2 Sell Ratings)
Consensus Price Target:
$53.00 (-0.7% Downside)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Bristol-Myers Squibb Stock

Pros

  • Bristol-Myers Squibb's stock price has been showing positive momentum, currently trading at $50.01, which indicates potential growth.
  • The company offers a diverse portfolio of biopharmaceutical products targeting various diseases, providing revenue stability.
  • Ongoing research and development efforts by Bristol-Myers Squibb may lead to the introduction of innovative treatments, potentially boosting stock value.

Cons

  • The pharmaceutical industry is subject to regulatory challenges and pricing pressures, impacting Bristol-Myers Squibb's profitability.
  • Market volatility and economic uncertainties can affect the company's stock price, leading to potential investment risks.
  • Competition from other pharmaceutical companies may limit Bristol-Myers Squibb's market share and revenue growth.
HCA Healthcare logo

#22 - HCA Healthcare

NYSE:HCA - See Stock Forecast
Stock Price:
$409.23 (+$7.97)
Market Cap:
$107.18 billion
P/E Ratio:
19.2
Dividend Yield:
0.67%
Consensus Rating:
Moderate Buy (3 Strong Buy Ratings, 14 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$365.65 (-10.6% Downside)
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Gilead Sciences logo

#23 - Gilead Sciences

NASDAQ:GILD - See Stock Forecast
Stock Price:
$86.75 (+$0.93)
Market Cap:
$106.92 billion
P/E Ratio:
105.8
Dividend Yield:
3.62%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 9 Buy Ratings, 10 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$84.83 (-2.2% Downside)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Gilead Sciences Stock

Pros

  • Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines in areas of unmet medical need.
  • The company offers a range of successful products such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Sunlencs.
  • Gilead Sciences, Inc. has a strong presence in the United States, Europe, and internationally, providing a diverse market for its products.

Cons

  • Despite its successes, Gilead Sciences, Inc. faces competition in the biopharmaceutical industry, which could impact its market share and profitability.
  • The company's stock price has been fluctuating in recent periods, indicating potential volatility in the market.
  • Changes in regulations and healthcare policies could affect Gilead Sciences, Inc.'s ability to bring new products to market and generate revenue.
The Cigna Group logo

#24 - The Cigna Group

NYSE:CI - See Stock Forecast
Stock Price:
$358.56 (+$9.72)
Market Cap:
$101.86 billion
P/E Ratio:
28.2
Dividend Yield:
1.59%
Consensus Rating:
Buy (1 Strong Buy Ratings, 13 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$392.79 (9.5% Upside)
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of The Cigna Group Stock

Pros

  • The Cigna Group stock has shown consistent growth, with a 1-year high of $370.83, indicating potential for capital appreciation.
  • Institutional investors, such as Silicon Valley Capital Partners and Cedar Wealth Management LLC, have been increasing their stakes in The Cigna Group, reflecting confidence in the company's future performance.
  • Analysts have given The Cigna Group a consensus rating of "Buy" with a target price of $392.79, suggesting further upside potential.

Cons

  • The stock's current price of $348.10 is below its 1-year high, suggesting potential volatility in the short term.
Zoetis logo

#25 - Zoetis

NYSE:ZTS - See Stock Forecast
Stock Price:
$194.45 (+$2.06)
Market Cap:
$88.10 billion
P/E Ratio:
38.1
Dividend Yield:
0.90%
Consensus Rating:
Buy (1 Strong Buy Ratings, 9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$221.44 (13.9% Upside)
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Zoetis Stock

Pros

  • Zoetis Inc. reported strong earnings results, beating analysts' consensus estimates, indicating a healthy financial performance.
  • The company has a high return on equity of 50.67%, showcasing efficient utilization of shareholder equity to generate profits.
  • Recent Wall Street analyst reports have given Zoetis Inc. positive ratings, with price targets indicating potential stock price growth.

Cons

  • Zoetis Inc.'s stock price has experienced fluctuations, which may introduce volatility and uncertainty for investors.
  • The company's price-to-earnings ratio of 37.86 suggests that the stock may be relatively expensive compared to industry peers, potentially limiting immediate upside potential.
  • While Zoetis Inc. has shown revenue growth, the price-to-earnings-growth ratio of 2.98 indicates that the stock may be overvalued based on its growth prospects.
CVS Health logo

#26 - CVS Health

NYSE:CVS - See Stock Forecast
Stock Price:
$65.01 (+$0.01)
Market Cap:
$81.61 billion
P/E Ratio:
11.6
Dividend Yield:
3.99%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 13 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$75.26 (15.8% Upside)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of CVS Health Stock

Pros

  • CVS Health Co. has a dividend yield of 4.58%, providing investors with a steady income stream. A higher dividend yield can be attractive to income-seeking investors.
  • Recent stock performance shows CVS Health Co. trading at $64.59, indicating a potential for capital appreciation. A rising stock price can lead to capital gains for investors.
  • CVS Health Co. reported a return on equity of 12.72%, showcasing the company's ability to generate profit from shareholders' equity. A higher return on equity is generally favorable for investors.

Cons

  • CVS Health Co. has a debt-to-equity ratio of 0.83, indicating a significant level of debt compared to equity. High debt levels can pose financial risks and impact the company's financial stability.
  • The company's stock price has experienced fluctuations, with a 52-week high of $83.25 and a 52-week low of $52.77. Volatility in stock prices can lead to uncertainty for investors.
  • CVS Health Co. has a beta of 0.54, suggesting lower volatility compared to the market. While lower volatility can be perceived as less risky, it may also limit potential returns for investors seeking higher-risk investments.
GSK logo

#27 - GSK

NYSE:GSK - See Stock Forecast
Stock Price:
$39.21 (+$0.25)
Market Cap:
$80.74 billion
P/E Ratio:
15.8
Dividend Yield:
3.94%
Consensus Rating:
Moderate Buy (3 Strong Buy Ratings, 2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$50.00 (27.5% Upside)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of GSK Stock

Pros

  • GSK plc has shown strong trading volume recently, indicating increased market interest and potential price movement.
  • Analysts have given GSK plc positive ratings, with some even upgrading it to a "strong-buy," suggesting confidence in the company's future performance.
  • GSK plc reported earnings per share of $1.09 for the last quarter, surpassing analyst estimates by $0.09, showcasing strong financial performance.

Cons

  • GSK plc's stock price has been relatively stagnant, with minor fluctuations, which may not appeal to investors seeking rapid capital appreciation.
  • The company's debt-to-equity ratio of 0.99 may raise concerns about its leverage levels and ability to manage debt obligations effectively.
  • While GSK plc has a strong net margin of 12.87%, there could be pressure on margins due to competitive pricing and regulatory challenges in the pharmaceutical industry.
Aetna logo

#28 - Aetna

NYSE:AET - See Stock Forecast
Stock Price:
$212.70
Market Cap:
$69.64 billion
P/E Ratio:
21.6
Dividend Yield:
0.94%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products comprising pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. was founded in 1853 and is based in Hartford, Connecticut.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Aetna Stock

Pros

  • Aetna Inc. has recently announced a detailed 2025 Medicare plan offering for its members, indicating a strategic focus on expanding its healthcare services.
  • The company operates in the Hospital & Medical Service Plans industry, which has shown resilience and growth potential, especially in times of economic uncertainty.
  • Aetna Inc. offers a diverse range of health care benefits, including medical, pharmacy, dental, and vision plans, catering to a wide customer base and enhancing revenue streams.

Cons

  • Regulatory changes in the healthcare sector could impact Aetna Inc.'s operations and profitability, leading to uncertainties for investors.
  • The competitive landscape in managed health care is intense, with other major players vying for market share, potentially affecting Aetna Inc.'s growth prospects.
  • Fluctuations in healthcare policies and reimbursement rates could pose challenges to Aetna Inc.'s financial performance and margins, impacting investor returns.
Becton, Dickinson and Company logo

#29 - Becton, Dickinson and Company

NYSE:BDX - See Stock Forecast
Stock Price:
$240.21 (-$1.61)
Market Cap:
$69.42 billion
P/E Ratio:
49.4
Dividend Yield:
1.61%
Consensus Rating:
Buy (0 Strong Buy Ratings, 8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$282.63 (17.7% Upside)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Becton, Dickinson and Company Stock

Pros

  • Becton, Dickinson and Company has consistently shown strong financial performance, with a return on equity of 14.49% and a net margin of 7.13%, indicating efficient use of shareholder equity and profitability.
  • The company has a stable dividend payout ratio of 83.70%, providing investors with a reliable income stream. The current dividend yield of 1.57% is attractive for income-oriented investors.
  • Analysts have given Becton, Dickinson and Company a "Moderate Buy" rating with an average target price of $279.50, suggesting potential for stock price appreciation.

Cons

  • While the company has shown solid financial performance, the stock's current PE ratio of 53.20 and P/E/G ratio of 1.92 may indicate that the stock is currently overvalued, potentially limiting short-term upside for investors.
  • The recent reduction in price targets by some analysts, such as Citigroup cutting the target from $260.00 to $255.00, may suggest concerns about future growth prospects or market conditions affecting the company.
  • Market volatility and economic uncertainties could impact Becton, Dickinson and Company's revenue growth, as seen in the slight revenue decline compared to analyst estimates in the latest earnings report.
McKesson logo

#30 - McKesson

NYSE:MCK - See Stock Forecast
Stock Price:
$510.93 (-$2.74)
Market Cap:
$66.39 billion
P/E Ratio:
22.9
Dividend Yield:
0.56%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 12 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$610.86 (19.6% Upside)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of McKesson Stock

Pros

  • McKesson Co. has a strong market capitalization of $63.45 billion, indicating stability and potential for growth in the market.
  • Recent quarterly earnings report showed McKesson Co. beating analysts' consensus estimates with $7.88 earnings per share, signaling strong financial performance.
  • McKesson Co. has a diverse range of services in the healthcare sector, operating through segments like U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International, providing a broad revenue base.

Cons

  • McKesson Co. has a negative return on equity of 242.57%, which may raise concerns about the company's profitability and efficiency in generating returns for shareholders.
  • The stock price of McKesson Co. has experienced fluctuations, with a 52-week low of $431.35 and a 52-week high of $637.51, indicating potential volatility in the market.
  • McKesson Co. operates in the healthcare sector, which can be subject to regulatory changes and uncertainties, impacting the company's operations and financial performance.
Allergan logo

#31 - Allergan

NYSE:AGN - See Stock Forecast
Stock Price:
$193.02
Market Cap:
$63.50 billion
Dividend Yield:
1.53%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Allergan Stock

Pros

  • Allergan plc has a diverse portfolio of products in various therapeutic areas, including medical aesthetics, dermatology, eye care, neuroscience, and more, providing a wide revenue stream.
  • The company is actively involved in developing innovative treatments for various conditions, such as therapies for liver diseases, autoimmune disorders, and neurodegenerative disorders, which could lead to significant market opportunities.
  • Allergan plc has strategic collaborations and licensing agreements with reputable companies like Editas Medicine, Inc. and Assembly Biosciences, Inc., enhancing its research and development capabilities.

Cons

  • The pharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact Allergan plc's product development timelines and market access.
  • Market volatility and economic uncertainties may affect the demand for healthcare products, potentially impacting Allergan plc's revenue and profitability.
  • Continued research and development expenses for innovative treatments may lead to short-term financial pressures on Allergan plc, affecting its bottom line.
Shire logo

#32 - Shire

NASDAQ:SHPG - See Stock Forecast
Stock Price:
$179.20
Market Cap:
$54.71 billion
P/E Ratio:
11.8
Dividend Yield:
0.19%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Express Scripts logo

#33 - Express Scripts

NASDAQ:ESRX - See Stock Forecast
Stock Price:
$92.33
Market Cap:
$52.06 billion
P/E Ratio:
13.0
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Express Scripts Stock

Pros

  • Express Scripts Holding has shown consistent growth in its PBM segment, offering a wide range of clinical solutions and specialized pharmacy care services, which indicates a strong revenue stream.
  • The company's focus on providing affordable access to medication through programs like Inside Rx can attract a larger customer base, potentially leading to increased market share and profitability.
  • Express Scripts Holding's diversified business operations, including specialty pharmaceutical distribution and medical benefit management solutions, provide stability and resilience in the ever-evolving healthcare industry.

Cons

  • Regulatory changes in the healthcare sector could impact Express Scripts Holding's operations and profitability, leading to uncertainties in the company's future performance.
  • Increased competition in the pharmacy benefit management industry may put pressure on Express Scripts Holding's market share and pricing power, affecting its overall financial performance.
  • Fluctuations in drug pricing and reimbursement policies could pose challenges to Express Scripts Holding's revenue generation and margins, impacting investor returns.
Cencora logo

#34 - Cencora

NYSE:COR - See Stock Forecast
Stock Price:
$236.60 (+$3.48)
Market Cap:
$47.19 billion
P/E Ratio:
25.7
Dividend Yield:
0.92%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 7 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$259.44 (9.7% Upside)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Cencora Stock

Pros

  • Cencora's stock price has been showing positive momentum, trading up to $228.11 on the latest trading day, indicating potential growth.
  • Major institutional investors like Vanguard Group Inc. and Price T Rowe Associates Inc. have recently added significant stakes in Cencora, reflecting confidence in the company's future prospects.
  • Analysts have given Cencora a consensus rating of "Moderate Buy" with an average price target of $256.67, suggesting room for stock price appreciation.

Cons

  • Insiders, including Walgreens Boots Alliance, Inc., have been selling significant amounts of Cencora stock, which could signal lack of confidence in the company's future performance.
  • Cencora's debt-to-equity ratio of 3.93 is relatively high, indicating higher financial leverage and potential risks in case of economic downturns.
  • While some analysts have given positive ratings, others have downgraded Cencora's stock, suggesting mixed opinions on the company's outlook.
Alcon logo

#35 - Alcon

NYSE:ALC - See Stock Forecast
Stock Price:
$95.29 (-$1.32)
Market Cap:
$46.99 billion
P/E Ratio:
42.9
Dividend Yield:
0.27%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 13 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$101.05 (6.0% Upside)
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Alcon Stock

Pros

  • Alcon Inc. has shown a positive Fifty-Two Week Performance of 11.11%.
  • Recent data indicates a Month-to-Month Change Percentage of 9.59%, suggesting potential growth.
  • With a low Short Percentage of Float at 0.87%, there is less short interest in the company.

Cons

  • The Institutional Ownership Percentage is 60.3%, which may lead to less volatility but also less potential for rapid price movements.
  • The Days to Cover ratio is 5.2, indicating a longer time for short sellers to cover their positions.
  • There has been a decrease in Shares Shorted from the previous month, which could indicate a lack of confidence in the stock.
Haleon logo

#36 - Haleon

NYSE:HLN - See Stock Forecast
Stock Price:
$10.13 (+$0.11)
Market Cap:
$46.26 billion
P/E Ratio:
33.8
Dividend Yield:
1.05%
Consensus Rating:
Buy (1 Strong Buy Ratings, 4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$10.95 (8.1% Upside)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Haleon Stock

Pros

  • Haleon plc's stock price has been steadily increasing, reaching $10.12 on the latest trading day, indicating positive momentum.
  • Analysts have given Haleon plc favorable ratings, with some even upgrading it to a "strong-buy" and setting a target price of $10.95, suggesting potential for growth.
  • Haleon plc recently announced a semi-annual dividend, providing investors with a 1.6% dividend yield, which can be attractive for income-focused investors.

Cons

  • Haleon plc's PEG ratio of 3.12 may indicate that the stock is overvalued relative to its earnings growth potential, potentially leading to limited upside for investors.
  • The company's payout ratio of 36.67% suggests that a significant portion of its earnings is being distributed as dividends, which could limit reinvestment for future growth.
  • Haleon plc's beta of 0.26 indicates low volatility compared to the market, which may result in slower price movements and potentially lower returns for investors seeking high-growth opportunities.
Takeda Pharmaceutical logo

#37 - Takeda Pharmaceutical

NYSE:TAK - See Stock Forecast
Stock Price:
$14.08 (+$0.03)
Market Cap:
$45.63 billion
P/E Ratio:
26.6
Dividend Yield:
3.32%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Takeda Pharmaceutical Stock

Pros

  • Takeda Pharmaceutical Company Limited reported a strong quarterly earnings performance, beating the consensus estimate by $0.19 per share, indicating positive growth potential.
  • The company has a healthy return on equity of 10.11%, showcasing efficient utilization of shareholder funds to generate profits.
  • With a low P/E ratio of 26.00 and a P/E/G ratio of 0.26, Takeda Pharmaceutical Company Limited's stock may be considered undervalued compared to its growth prospects.

Cons

  • The stock price of Takeda Pharmaceutical Company Limited has been relatively stagnant, trading within a narrow range, potentially limiting short-term capital appreciation.
  • Despite a strong quarterly performance, the company's debt-to-equity ratio of 0.65 may raise concerns about its financial leverage and ability to manage debt obligations.
  • While the company has shown growth potential, the beta of 0.54 indicates lower volatility compared to the market, potentially limiting short-term trading opportunities.
Seagen logo

#38 - Seagen

NASDAQ:SGEN - See Stock Forecast
Stock Price:
$228.74
Market Cap:
$42.93 billion
Consensus Rating:
Hold (0 Strong Buy Ratings, 0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$229.00 (0.1% Upside)
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Seagen Stock

Pros

  • Seagen Inc. has shown a positive Month-to-Month Change Percentage in short interest, indicating potential stability in the stock.
  • The institutional ownership percentage of Seagen Inc. is high at 91.8%, suggesting confidence from large financial institutions.
  • Seagen Inc. has a Days to Cover ratio of 7.2, which indicates the number of days it would take for short sellers to cover their positions based on the average daily volume.

Cons

  • Seagen Inc. has a relatively high level of shares shorted, which could indicate bearish sentiment in the market.
  • The Fifty-Two Week Performance of Seagen Inc. stands at 55.37%, which may not be as strong compared to other companies in the same sector.
  • The Short Percentage of Float for Seagen Inc. is 0, which could suggest limited short-term trading opportunities.
IQVIA logo

#39 - IQVIA

NYSE:IQV - See Stock Forecast
Stock Price:
$233.06 (+$0.08)
Market Cap:
$42.46 billion
P/E Ratio:
30.3
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 12 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$267.87 (14.9% Upside)
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of IQVIA Stock

Pros

  • IQVIA Holdings Inc. has shown consistent revenue growth over recent quarters, indicating a strong financial performance.
  • Analysts have been upgrading their price targets for IQVIA Holdings Inc., suggesting positive sentiment and potential for stock price appreciation.
  • IQVIA Holdings Inc. reported earnings per share (EPS) that exceeded analysts' estimates, demonstrating strong profitability.

Cons

  • The stock's current price may be considered high based on its historical valuation metrics, potentially limiting short-term upside.
  • There could be regulatory risks associated with the healthcare and life sciences industry that may impact IQVIA Holdings Inc.'s operations and profitability.
  • Competition in the industry from other research and analytics companies could pose a challenge to IQVIA Holdings Inc.'s market share and growth prospects.
Edwards Lifesciences logo

#40 - Edwards Lifesciences

NYSE:EW - See Stock Forecast
Stock Price:
$68.30 (-$0.60)
Market Cap:
$41.52 billion
P/E Ratio:
28.1
Consensus Rating:
Hold (1 Strong Buy Ratings, 10 Buy Ratings, 14 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$75.81 (11.0% Upside)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Edwards Lifesciences Stock

Pros

  • Edwards Lifesciences Co. reported positive quarterly earnings results, beating analysts' expectations, which indicates strong financial performance.
  • The company has a solid net margin of 24.55%, showcasing efficient cost management and profitability.
  • Recent insider selling activities could be seen as a positive sign, indicating confidence in the company's future growth prospects.

Cons

  • The company's stock has experienced a decline in price, which may raise concerns about future performance and market sentiment.
  • Analysts have adjusted price targets downwards, indicating potential challenges or uncertainties in the company's growth trajectory.
  • Edwards Lifesciences Co. has a beta of 1.13, suggesting higher volatility compared to the market average, which could lead to increased risk for investors.
These 5 stocks could soar after November 4th (Ad)

Earnings Season: Your FREE Ticket to Trading Success Don't just survive earnings season - learn how to potentially thrive. Discover how to time your trades for maximum potential profit. Bonus: Daily earnings updates delivered straight to your inbox.

Click here now to claim your free guide before this offer expires!
GE HealthCare Technologies logo

#41 - GE HealthCare Technologies

NASDAQ:GEHC - See Stock Forecast
Stock Price:
$90.22 (-$0.49)
Market Cap:
$41.18 billion
P/E Ratio:
26.2
Dividend Yield:
0.13%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 7 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$94.23 (4.4% Upside)
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of GE HealthCare Technologies Stock

Pros

  • GE HealthCare Technologies Inc. has recently announced a quarterly dividend of $0.03 per share, providing investors with a steady income stream.
  • BTIG Research upgraded GE HealthCare Technologies from a "neutral" to a "buy" rating with a price target of $100.00, indicating potential for stock price appreciation.
  • GE HealthCare Technologies reported earnings per share of $1.00 for the last quarter, surpassing analyst estimates, showcasing strong financial performance.

Cons

  • UBS Group downgraded GE HealthCare Technologies from a "neutral" to a "sell" rating, indicating potential concerns about the company's performance.
  • The stock price of GE HealthCare Technologies Inc. has decreased by 0.5% recently, which may raise doubts about short-term stock performance.
  • GE HealthCare Technologies Inc. has a debt-to-equity ratio of 1.05, suggesting a relatively high level of debt that could impact financial stability.
Alexion Pharmaceuticals logo

#42 - Alexion Pharmaceuticals

NASDAQ:ALXN - See Stock Forecast
Stock Price:
$182.50
Market Cap:
$40.34 billion
P/E Ratio:
59.6
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Alexion Pharmaceuticals Stock

Pros

  • Alexion Pharmaceuticals, Inc. has recently announced successful clinical trials for a groundbreaking treatment, which is expected to drive significant revenue growth.
  • The company's strong pipeline of innovative drugs, including a potential game-changing therapy for a rare disease, positions it well for future success.
  • Recent financial reports indicate a steady increase in revenue and profitability, showcasing the company's financial stability and growth potential.

Cons

  • Regulatory uncertainties surrounding one of the company's key products could impact future sales and profitability, leading to potential volatility in the stock price.
  • Competitive pressures in the pharmaceutical industry may pose challenges to Alexion Pharmaceuticals, Inc.'s market share and pricing power, affecting its overall financial performance.
  • Recent controversies related to data breaches and privacy issues could tarnish the company's reputation and erode investor trust, potentially impacting its long-term growth prospects.
IDEXX Laboratories logo

#43 - IDEXX Laboratories

NASDAQ:IDXX - See Stock Forecast
Stock Price:
$463.89 (-$10.03)
Market Cap:
$38.31 billion
P/E Ratio:
45.9
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$574.13 (23.8% Upside)
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Centene logo

#44 - Centene

NYSE:CNC - See Stock Forecast
Stock Price:
$69.29 (+$0.81)
Market Cap:
$36.98 billion
P/E Ratio:
13.1
Consensus Rating:
Hold (0 Strong Buy Ratings, 6 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$85.58 (23.5% Upside)
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Centene Stock

Pros

  • Centene Co. has shown consistent revenue growth over recent quarters, indicating a strong financial performance.
  • With a return on equity of 14.45%, Centene Co. demonstrates efficient use of shareholder funds to generate profits.
  • Centene Co.'s current stock price of $75.61 presents a potential buying opportunity for investors looking to enter at a reasonable valuation.

Cons

  • Centene Co. missed analysts' consensus estimates in its recent quarterly earnings report, which may raise concerns about its ability to meet expectations.
  • The company's net margin of 1.79% indicates relatively low profitability compared to industry peers, potentially impacting investor returns.
  • Centene Co. has a debt-to-equity ratio of 0.64, suggesting a moderate level of financial leverage that could pose risks in uncertain economic conditions.
Alnylam Pharmaceuticals logo

#45 - Alnylam Pharmaceuticals

NASDAQ:ALNY - See Stock Forecast
Stock Price:
$300.55 (+$13.19)
Market Cap:
$36.35 billion
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 18 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$286.82 (-4.6% Downside)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Alnylam Pharmaceuticals Stock

Pros

  • Alnylam Pharmaceuticals, Inc. reported a significant increase in revenue, up 107.0% year-over-year, indicating strong growth potential.
  • The company beat analysts' EPS estimates by $0.61, showcasing strong financial performance.
  • Analysts have set a high price target for Alnylam Pharmaceuticals, Inc., with a consensus target of $279.14, suggesting potential for stock price appreciation.

Cons

  • Despite positive analyst ratings, there are still some hold ratings on the stock, suggesting potential risks or uncertainties.
  • Insiders have been selling shares of Alnylam Pharmaceuticals, Inc., which could be perceived as a lack of confidence in the company's future performance.
  • Stock price volatility may be a concern for investors, as the stock has experienced fluctuations in recent trading sessions.
ResMed logo

#46 - ResMed

NYSE:RMD - See Stock Forecast
Stock Price:
$238.46 (-$0.72)
Market Cap:
$35.03 billion
P/E Ratio:
34.4
Dividend Yield:
0.88%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 6 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$218.18 (-8.5% Downside)
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of ResMed Stock

Pros

  • ResMed Inc. has consistently increased its dividend payouts, indicating financial stability and potential for income generation for investors. The current annualized dividend yield of 0.89% is attractive for income-focused investors.
  • Analysts have set a new price target for ResMed Inc. at $213.75, suggesting potential for stock price appreciation based on market expectations.
  • Institutional investors have been actively increasing their stakes in ResMed Inc., signaling confidence in the company's growth prospects and financial performance.

Cons

  • ResMed Inc.'s stock price has been volatile in recent periods, which may pose risks for short-term investors looking for stable returns.
  • There is a sell rating from one investment analyst on ResMed Inc., suggesting some concerns about the company's performance or market conditions.
  • While the company has a moderate buy consensus rating, there are also hold ratings, indicating mixed opinions from analysts on the stock's future performance.
argenx logo

#47 - argenx

NASDAQ:ARGX - See Stock Forecast
Stock Price:
$540.61 (-$4.10)
Market Cap:
$32.37 billion
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 17 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$548.00 (1.4% Upside)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Humana logo

#48 - Humana

NYSE:HUM - See Stock Forecast
Stock Price:
$255.57 (-$2.03)
Market Cap:
$31.04 billion
P/E Ratio:
18.2
Dividend Yield:
1.32%
Consensus Rating:
Hold (0 Strong Buy Ratings, 6 Buy Ratings, 18 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$315.33 (23.4% Upside)
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Humana Stock

Pros

  • Humana's stock price has shown resilience, currently trading at a lower price, potentially presenting a buying opportunity for investors.
  • Humana has consistently delivered strong quarterly earnings results, surpassing analyst expectations, indicating a healthy financial performance.
  • With a dividend yield of 1.11%, Humana offers investors a steady income stream through regular dividend payments.

Cons

  • Humana's stock price has experienced a significant decline, potentially indicating underlying issues or market concerns.
  • Recent rating adjustments by analysts, including downgrades and lowered price targets, may signal uncertainties surrounding the company's future performance.
  • Humana's PEG ratio of 2.44 suggests a relatively high valuation compared to its expected earnings growth, potentially limiting upside potential for investors.
Koninklijke Philips logo

#49 - Koninklijke Philips

NYSE:PHG - See Stock Forecast
Stock Price:
$32.28 (+$0.15)
Market Cap:
$30.34 billion
Dividend Yield:
2.85%
Consensus Rating:
Hold (0 Strong Buy Ratings, 1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease. In addition, the company offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. Further, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental solutions; and grooming and beauty products and solutions. The company has strategic partnership agreements with TriHealth, Northwell, and Atrium Health. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Koninklijke Philips Stock

Pros

  • Koninklijke Philips has shown consistent growth in revenue and earnings, indicating a strong financial performance.
  • The company's recent positive earnings report, with $0.32 earnings per share and $4.80 billion in revenue, demonstrates financial stability.
  • With a market capitalization of $30.75 billion, Koninklijke Philips is a significant player in the technology sector, offering stability and potential growth.

Cons

  • Despite recent positive performance, Koninklijke Philips has a negative net margin of 2.35%, indicating potential financial challenges.
  • The company's P/E ratio of -34.08 may raise concerns about overvaluation or market expectations that could impact stock performance.
  • Koninklijke Philips has a debt-to-equity ratio of 0.60, which suggests a moderate level of financial leverage that could affect future financial health.
Mettler-Toledo International logo

#50 - Mettler-Toledo International

NYSE:MTD - See Stock Forecast
Stock Price:
$1,402.67 (-$50.73)
Market Cap:
$29.96 billion
P/E Ratio:
38.6
Consensus Rating:
Reduce (0 Strong Buy Ratings, 1 Buy Ratings, 5 Hold Ratings, 2 Sell Ratings)
Consensus Price Target:
$1,363.75 (-2.8% Downside)
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection equipment, x-ray systems, check weighing equipment, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of weighing and software solutions, AI-driven image recognition solution, and automated packaging and labelling solutions for the meat backroom. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Mettler-Toledo International Stock

Pros

  • Metler-Toledo International Inc. stock price has been steadily increasing, reaching $1,383.06 on the latest trading day, indicating positive market sentiment.
  • The company reported strong quarterly earnings results, surpassing analysts' expectations with an EPS of $9.65, which could attract more investors seeking profitable opportunities.
  • With a market cap of $29.35 billion, Mettler-Toledo International Inc. is considered a large-cap company, providing stability and potential for long-term growth.

Cons

  • Despite positive earnings, the company experienced a decrease in revenue by 3.6% on a year-over-year basis, indicating potential challenges in maintaining revenue growth.
  • The stock has a price-to-earnings ratio of 38.78, which may be considered high by some investors, potentially limiting its attractiveness compared to lower P/E ratio stocks.
  • Mettler-Toledo International Inc. had a negative return on equity of 575.61%, reflecting operational inefficiencies that could impact shareholder returns.

(Ad)

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.

More Stock Ideas from MarketBeat